Quimioterapia |
Younes et al.(6868 Younes RN, Pereira JR, Fares AL, Gross JL. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras (1992). 2011;57(6):686-91. https://doi.org/10.1590/S0104-42302011000600017
https://doi.org/10.1590/S0104-4230201100...
)
|
Re |
2.673 |
1990-2008 |
49a
|
Privada |
8,0 |
Naime et al.(6969 Naime FF, Younes RN, Kersten BG, Anelli A, Beato CA, Andrade RM, et al. Metastatic non-small cell lung cancer in Brazil: treatment heterogeneity in routine clinical practice. Clinics (Sao Paulo). 2007;62(4):397-404. https://doi.org/10.1590/S1807-59322007000400005
https://doi.org/10.1590/S1807-5932200700...
)
|
Re |
564 |
1990-2003 |
47 |
Privada |
8,3 |
Araujo et al.(2323 Araujo LH, Baldotto CS, Zukin M, Vieira FM, Victorino AP, Rocha VR, et al. Survival and prognostic factors in patients with non-small cell lung cancer treated in private health care. Rev Bras Epidemiol. 2014;17(4):1001-14. https://doi.org/10.1590/1809-4503201400040017
https://doi.org/10.1590/1809-45032014000...
)
|
Re |
339 |
1998-2010 |
11 |
Privada |
12,2 |
Leite et al.(7575 Leite GM, França MVS, Santana LM, Taveira MC, Zanardo G, Teles LT, et al. Descrição epidemiológica e clínica dos pacientes com câncer de pulmão tratados no Hospital Universitário de Brasília. Proceedings of the XVIII Congresso da Sociedade Brasileira de Oncologia Clínica. Brasília; 2013 Oct 23-26; São Paulo: Sociedade Brasileira de Oncologia Clínica. 606.)
|
Re |
163 |
2006-2013 |
ND |
Pública |
ND |
Zukin et al.(7070 Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol. 2013;31(23):2849-53. https://doi.org/10.1200/JCO.2012.48.1911
https://doi.org/10.1200/JCO.2012.48.1911...
)
|
Pro |
205 |
2008-2011 |
100 |
Pública |
5,3/9,3b
|
Pereira et al.(7676 Pereira AA, Martins SJ, Lessa RC, Pinto FA, Gagliato DM, Santos ES, et al. Comparison of bevacizumab versus pemetrexed in combination with platinum-based doublets in first-line treatment of advanced non-small cell lung cancer. J Clin Oncol, 2012. 30;15 Suppl:e18078.)
|
Re |
82 |
2007-2011 |
ND |
Privada |
26,4/16,4c
|
Jardim et al.(7777 Jardim DL, Gagliato Dde M, Ribeiro KB, Shimada AK, Katz A. Bevacizumab as first-line therapy in advanced non-small-cell lung cancer: a Brazilian center experience. Drugs R D. 2012;12(4):207-16. https://doi.org/10.2165/11636760-000000000-00000
https://doi.org/10.2165/11636760-0000000...
)
|
Re |
56 |
2006-2011 |
7,2 |
Privada |
14,8 |
Pereira et al.(7171 Pereira JR, Martins SJ, Nikaedo SM, Ikari FK. Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC). BMC Cancer. 2004;4:69. https://doi.org/10.1186/1471-2407-4-69
https://doi.org/10.1186/1471-2407-4-69...
)
|
Pro |
44 |
1996-1998 |
50a
|
Pública |
7,5d
|
ITQ do EGFR |
Caires-Lima et al.(7272 Caires-Lima R, et al. Erlotinib in metastatic pulmonary adenocarcinomas harbouring EGFR activating mutations in São Paulo--Brazil. Proceedings of the 15th World Conference on Lung Cancer; 2013 Oct 27-30; Sydney: Australia. Aurora (USA): IASLC; 2015. P2.11-009.)
|
Re |
49 |
2010-2013 |
ND |
Pública |
NAe
|
Domingues et al.(4343 Domingues PM, Montella T, Zukin M, Baldotto C, Ferreira C. Epidemiology and clinical outcomes of epidermal growth factor receptor (EGFR) mutant patients at the Brazilian National Cancer Institute (INCA). Proceedings of the 16th World Conference on Lung Cancer; 2015 Sep 6-9; Denver: USA. Aurora (USA): IASLC; 2015. P2.04-032.)
|
Re |
32 |
2011-2014 |
ND |
Pública |
62,9 |
Freitas et al.(7373 Freitas HC, Saito AO, Santos FN, Cunha IW, Dettino ALA, Macedo MP, et al. Treatment and clinical evolution of a cohort of 105 EGFR mutant patients from a single institution. Proceedings of the 16th World Conference on Lung Cancer; 2015 Sep 6-9; Denver: USA. Aurora (USA): IASLC; 2015. P3.01-019.)
|
Re |
61 |
2010-2014 |
ND |
Privada |
36,3/NAf
|